Dyadic International (NASDAQ:DYAI) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?

Shares of Dyadic International Inc. (NASDAQ:DYAI) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.81 and traded as low as $0.7251. Dyadic International shares last traded at $0.7376, with a volume of 12,497 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Dyadic International Trading Up 2.3%

The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. The stock has a market capitalization of $26.88 million, a PE ratio of -3.21 and a beta of 1.18. The stock’s 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $0.87.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, sell-side analysts expect that Dyadic International Inc. will post -0.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the last quarter. Marathon Capital Management lifted its stake in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares in the last quarter. Apis Capital Advisors LLC purchased a new stake in shares of Dyadic International during the 3rd quarter valued at approximately $1,817,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International during the 3rd quarter valued at approximately $190,000. Finally, Truist Financial Corp lifted its stake in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.